| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| - - | HOLD | 0 @ USD 0 | USD 0 | |
| THRD - Third Harmonic Bio Inc. | HOLD | 0 @ USD 0.0300173 | USD 0 | The current share valuation price of THRD based on adjusted close was USD 0.0300173. The average price that THRD shares were previous bought at was USD 5.06885. The current market price is -99.4% lower than average price they were purchased at. USD 0 compared to the previous valuation of Third Harmonic Bio Inc. however if the holding was sold on 2025-11-20 this would crystalise an overall loss. |
| OKUR - OKUR | SELL | -84 @ USD 2.61994 | USD -220 | The ETF sold 84 shares of OKUR on 2025-11-20. The shares were previously bought for an average price of USD 6.00266. The OKUR shares were sold for -56.4% lower than average price of previous purchases. This resulted in an overall loss of USD 284 The average price that the ETF previously sold OKUR share for is USD 4.67141 which is higher than the selling price of USD 2.61994 on 2025-11-20. |
| STRO - Sutro Biopharma | SELL | -544 @ USD 0.846592 | USD -461 | The ETF sold 544 shares of STRO on 2025-11-20. The shares were previously bought for an average price of USD 0.898862. The Sutro Biopharma shares were sold for -5.8% lower than average price of previous purchases. This resulted in an overall loss of USD 28 The average price that the ETF previously sold STRO share for is USD 0.848365 which is higher than the selling price of USD 0.846592 on 2025-11-20. |
| BMEA - Biomea Fusion Inc | SELL | -476 @ USD 1 | USD -476 | The ETF sold 476 shares of BMEA on 2025-11-20. The shares were previously bought for an average price of USD 1.73607. The Biomea Fusion Inc shares were sold for -42.4% lower than average price of previous purchases. This resulted in an overall loss of USD 350 The average price that the ETF previously sold BMEA share for is USD 3.19044 which is higher than the selling price of USD 1 on 2025-11-20. |
| MGNX - MacroGenics Inc | SELL | -428 @ USD 1.37 | USD -586 | The ETF sold 428 shares of MGNX on 2025-11-20. The shares were previously bought for an average price of USD 1.57275. The MacroGenics Inc shares were sold for -12.9% lower than average price of previous purchases. This resulted in an overall loss of USD 87 The average price that the ETF previously sold MGNX share for is USD 2.21418 which is higher than the selling price of USD 1.37 on 2025-11-20. |
| PLRX - Pliant Therapeutics Inc | SELL | -400 @ USD 1.55999 | USD -624 | The ETF sold 400 shares of PLRX on 2025-11-20. The shares were previously bought for an average price of USD 1.50179. The Pliant Therapeutics Inc shares were sold for 3.9% higher than average price of previous purchases. This sale made a profit of USD 23 The average price that the ETF previously sold PLRX share for is USD 6.56466 which is higher than the selling price of USD 1.55999 on 2025-11-20. |
| FATE - Fate Therapeutics Inc | SELL | -756 @ USD 1 | USD -756 | The ETF sold 756 shares of FATE on 2025-11-20. The shares were previously bought for an average price of USD 1.1753. The Fate Therapeutics Inc shares were sold for -14.9% lower than average price of previous purchases. This resulted in an overall loss of USD 133 The average price that the ETF previously sold FATE share for is USD 1.02787 which is higher than the selling price of USD 1 on 2025-11-20. |
| ALEC - Alector Inc | SELL | -732 @ USD 1.19999 | USD -878 | The ETF sold 732 shares of ALEC on 2025-11-20. The shares were previously bought for an average price of USD 1.88122. The Alector Inc shares were sold for -36.2% lower than average price of previous purchases. This resulted in an overall loss of USD 499 The average price that the ETF previously sold ALEC share for is USD 1.957 which is higher than the selling price of USD 1.19999 on 2025-11-20. |
| MRSN - Mersana Therapeutics Inc | SELL | -32 @ USD 27.51 | USD -880 | The ETF sold 32 shares of MRSN on 2025-11-20. The shares were previously bought for an average price of USD 0.674564. The Mersana Therapeutics Inc shares were sold for 3,978.2% higher than average price of previous purchases. This sale made a profit of USD 859 The average price that the ETF previously sold MRSN share for is USD 5.95796 so the ETF has sold 32 shares on 2025-11-20 at a higher price than the previous selling average. |
| ARCT - Arcturus Therapeutics Holdings Inc | SELL | -196 @ USD 5.9 | USD -1,156 | The ETF sold 196 shares of ARCT on 2025-11-20. The shares were previously bought for an average price of USD 14.1583. The Arcturus Therapeutics Holdings Inc shares were sold for -58.3% lower than average price of previous purchases. This resulted in an overall loss of USD 1,619 The average price that the ETF previously sold ARCT share for is USD 14.6394 which is higher than the selling price of USD 5.9 on 2025-11-20. |
| MXCT - MaxCyte Inc | SELL | -740 @ USD 1.63 | USD -1,206 | The ETF sold 740 shares of MXCT on 2025-11-20. The shares were previously bought for an average price of USD 2.14582. The MaxCyte Inc shares were sold for -24.0% lower than average price of previous purchases. This resulted in an overall loss of USD 382 The average price that the ETF previously sold MXCT share for is USD 2.8317 which is higher than the selling price of USD 1.63 on 2025-11-20. |
| HUMA - Humacyte Inc | SELL | -1,124 @ USD 1.12 | USD -1,259 | The ETF sold 1124 shares of HUMA on 2025-11-20. The shares were previously bought for an average price of USD 2.16752. The Humacyte Inc shares were sold for -48.3% lower than average price of previous purchases. This resulted in an overall loss of USD 1,177 The average price that the ETF previously sold HUMA share for is USD 2.85916 which is higher than the selling price of USD 1.12 on 2025-11-20. |
| OABI - OmniAb Inc. | SELL | -856 @ USD 1.67 | USD -1,430 | The ETF sold 856 shares of OABI on 2025-11-20. The shares were previously bought for an average price of USD 1.89326. The OmniAb Inc. shares were sold for -11.8% lower than average price of previous purchases. This resulted in an overall loss of USD 191 The average price that the ETF previously sold OABI share for is USD 2.79205 which is higher than the selling price of USD 1.67 on 2025-11-20. |
| VYGR - Voyager Therapeutics Inc | SELL | -356 @ USD 4.08999 | USD -1,456 | The ETF sold 356 shares of VYGR on 2025-11-20. The shares were previously bought for an average price of USD 3.87. The Voyager Therapeutics Inc shares were sold for 5.7% higher than average price of previous purchases. This sale made a profit of USD 78 The average price that the ETF previously sold VYGR share for is USD 4.7153 which is higher than the selling price of USD 4.08999 on 2025-11-20. |
| EDIT - Editas Medicine Inc | SELL | -660 @ USD 2.47 | USD -1,630 | The ETF sold 660 shares of EDIT on 2025-11-20. The shares were previously bought for an average price of USD 2.73158. The Editas Medicine Inc shares were sold for -9.6% lower than average price of previous purchases. This resulted in an overall loss of USD 173 The average price that the ETF previously sold EDIT share for is USD 1.98834 so the ETF has sold 660 shares on 2025-11-20 at a higher price than the previous selling average. |
| AVIR - Atea Pharmaceuticals Inc | SELL | -576 @ USD 3 | USD -1,728 | The ETF sold 576 shares of AVIR on 2025-11-20. The shares were previously bought for an average price of USD 3.32256. The Atea Pharmaceuticals Inc shares were sold for -9.7% lower than average price of previous purchases. This resulted in an overall loss of USD 186 The average price that the ETF previously sold AVIR share for is USD 3.15225 which is higher than the selling price of USD 3 on 2025-11-20. |
| AUTL - Autolus Therapeutics Ltd | SELL | -1,496 @ USD 1.23 | USD -1,840 | The ETF sold 1496 shares of AUTL on 2025-11-20. The shares were previously bought for an average price of USD 1.82293. The Autolus Therapeutics Ltd shares were sold for -32.5% lower than average price of previous purchases. This resulted in an overall loss of USD 887 The average price that the ETF previously sold AUTL share for is USD 2.11462 which is higher than the selling price of USD 1.23 on 2025-11-20. |
| AVXL - Anavex Life Sciences Corp | SELL | -588 @ USD 3.16999 | USD -1,864 | The ETF sold 588 shares of AVXL on 2025-11-20. The shares were previously bought for an average price of USD 9.22805. The Anavex Life Sciences Corp shares were sold for -65.6% lower than average price of previous purchases. This resulted in an overall loss of USD 3,562 The average price that the ETF previously sold AVXL share for is USD 9.43149 which is higher than the selling price of USD 3.16999 on 2025-11-20. |
| ALLO - Allogene Therapeutics Inc | SELL | -1,508 @ USD 1.24 | USD -1,870 | The ETF sold 1508 shares of ALLO on 2025-11-20. The shares were previously bought for an average price of USD 1.32993. The Allogene Therapeutics Inc shares were sold for -6.8% lower than average price of previous purchases. This resulted in an overall loss of USD 136 The average price that the ETF previously sold ALLO share for is USD 1.83901 which is higher than the selling price of USD 1.24 on 2025-11-20. |
| ACIU - AC Immune Ltd | SELL | -684 @ USD 2.91 | USD -1,990 | The ETF sold 684 shares of ACIU on 2025-11-20. The shares were previously bought for an average price of USD 2.44386. The AC Immune Ltd shares were sold for 19.1% higher than average price of previous purchases. This sale made a profit of USD 319 The average price that the ETF previously sold ACIU share for is USD 2.32056 so the ETF has sold 684 shares on 2025-11-20 at a higher price than the previous selling average. |
| BCYC - Bicycle Therapeutics Ltd | SELL | -324 @ USD 6.16999 | USD -1,999 | The ETF sold 324 shares of BCYC on 2025-11-20. The shares were previously bought for an average price of USD 8.45276. The Bicycle Therapeutics Ltd shares were sold for -27.0% lower than average price of previous purchases. This resulted in an overall loss of USD 740 The average price that the ETF previously sold BCYC share for is USD 10.7737 which is higher than the selling price of USD 6.16999 on 2025-11-20. |
| RCKT - Rocket Pharmaceuticals Inc | SELL | -732 @ USD 2.84 | USD -2,079 | The ETF sold 732 shares of RCKT on 2025-11-20. The shares were previously bought for an average price of USD 5.01477. The Rocket Pharmaceuticals Inc shares were sold for -43.4% lower than average price of previous purchases. This resulted in an overall loss of USD 1,592 The average price that the ETF previously sold RCKT share for is USD 8.79382 which is higher than the selling price of USD 2.84 on 2025-11-20. |
| VNDA - Vanda Pharmaceuticals Inc | SELL | -436 @ USD 4.84 | USD -2,110 | The ETF sold 436 shares of VNDA on 2025-11-20. The shares were previously bought for an average price of USD 4.85899. The Vanda Pharmaceuticals Inc shares were sold for -0.4% lower than average price of previous purchases. This resulted in an overall loss of USD 8 The average price that the ETF previously sold VNDA share for is USD 4.75144 so the ETF has sold 436 shares on 2025-11-20 at a higher price than the previous selling average. |
| LYEL - Lyell Immunopharma Inc | SELL | -128 @ USD 17.43 | USD -2,231 | The ETF sold 128 shares of LYEL on 2025-11-20. The shares were previously bought for an average price of USD 6.6399. The Lyell Immunopharma Inc shares were sold for 162.5% higher than average price of previous purchases. This sale made a profit of USD 1,381 The average price that the ETF previously sold LYEL share for is USD 6.63593 so the ETF has sold 128 shares on 2025-11-20 at a higher price than the previous selling average. |
| TRDA - Entrada Therapeutics Inc | SELL | -276 @ USD 9.16999 | USD -2,531 | The ETF sold 276 shares of TRDA on 2025-11-20. The shares were previously bought for an average price of USD 7.68886. The Entrada Therapeutics Inc shares were sold for 19.3% higher than average price of previous purchases. This sale made a profit of USD 409 The average price that the ETF previously sold TRDA share for is USD 8.35116 so the ETF has sold 276 shares on 2025-11-20 at a higher price than the previous selling average. |
| ALT - Altitude Group Plc | SELL | -576 @ USD 4.47 | USD -2,575 | The ETF sold 576 shares of ALT on 2025-11-20. The shares were previously bought for an average price of USD 5.15301. The Altitude Group Plc shares were sold for -13.3% lower than average price of previous purchases. This resulted in an overall loss of USD 393 The average price that the ETF previously sold ALT share for is USD 4.70944 which is higher than the selling price of USD 4.47 on 2025-11-20. |
| SIGA - SIGA Technologies Inc | SELL | -476 @ USD 5.76999 | USD -2,747 | The ETF sold 476 shares of SIGA on 2025-11-20. The shares were previously bought for an average price of USD 6.76989. The SIGA Technologies Inc shares were sold for -14.8% lower than average price of previous purchases. This resulted in an overall loss of USD 476 The average price that the ETF previously sold SIGA share for is USD 6.66928 which is higher than the selling price of USD 5.76999 on 2025-11-20. |
| HCM - HUTCHMED China Ltd | SELL | -212 @ USD 14.18 | USD -3,006 | The ETF sold 212 shares of HCM on 2025-11-20. The shares were previously bought for an average price of USD 15.4568. The HUTCHMED China Ltd shares were sold for -8.3% lower than average price of previous purchases. This resulted in an overall loss of USD 271 The average price that the ETF previously sold HCM share for is USD 15.1435 which is higher than the selling price of USD 14.18 on 2025-11-20. |
| HCM - Hitachi Construction Machinery Co. Ltd | SELL | -212 @ USD 14.18 | USD -3,006 | The ETF sold 212 shares of HCM on 2025-11-20. The shares were previously bought for an average price of USD 15.4568. The Hitachi Construction Machinery Co. Ltd shares were sold for -8.3% lower than average price of previous purchases. This resulted in an overall loss of USD 271 The average price that the ETF previously sold HCM share for is USD 15.1435 which is higher than the selling price of USD 14.18 on 2025-11-20. |
| GLPG - Galapagos NV ADR | SELL | -100 @ USD 30.24 | USD -3,024 | The ETF sold 100 shares of GLPG on 2025-11-20. The shares were previously bought for an average price of USD 29.2343. The Galapagos NV ADR shares were sold for 3.4% higher than average price of previous purchases. This sale made a profit of USD 101 The average price that the ETF previously sold GLPG share for is USD 27.2319 so the ETF has sold 100 shares on 2025-11-20 at a higher price than the previous selling average. |
| GLPG - Galapagos N.V. | SELL | -100 @ USD 30.24 | USD -3,024 | The ETF sold 100 shares of GLPG on 2025-11-20. The shares were previously bought for an average price of USD 29.2343. The Galapagos N.V. shares were sold for 3.4% higher than average price of previous purchases. This sale made a profit of USD 101 The average price that the ETF previously sold GLPG share for is USD 27.2319 so the ETF has sold 100 shares on 2025-11-20 at a higher price than the previous selling average. |
| EOLS - Evolus Inc | SELL | -472 @ USD 6.61999 | USD -3,125 | The ETF sold 472 shares of EOLS on 2025-11-20. The shares were previously bought for an average price of USD 9.0839. The Evolus Inc shares were sold for -27.1% lower than average price of previous purchases. This resulted in an overall loss of USD 1,163 The average price that the ETF previously sold EOLS share for is USD 10.9887 which is higher than the selling price of USD 6.61999 on 2025-11-20. |
| IRWD - Ironwood Pharmaceuticals Inc | SELL | -1,032 @ USD 3.17 | USD -3,271 | The ETF sold 1032 shares of IRWD on 2025-11-20. The shares were previously bought for an average price of USD 1.29361. The Ironwood Pharmaceuticals Inc shares were sold for 145.1% higher than average price of previous purchases. This sale made a profit of USD 1,936 The average price that the ETF previously sold IRWD share for is USD 2.65828 so the ETF has sold 1032 shares on 2025-11-20 at a higher price than the previous selling average. |
| LXRX - Lexicon Pharmaceuticals Inc | SELL | -2,544 @ USD 1.32 | USD -3,358 | The ETF sold 2544 shares of LXRX on 2025-11-20. The shares were previously bought for an average price of USD 1.07525. The Lexicon Pharmaceuticals Inc shares were sold for 22.8% higher than average price of previous purchases. This sale made a profit of USD 623 The average price that the ETF previously sold LXRX share for is USD 0.739327 so the ETF has sold 2544 shares on 2025-11-20 at a higher price than the previous selling average. |
| FDMT - 4D Molecular Therapeutics Inc | SELL | -336 @ USD 10.34 | USD -3,474 | The ETF sold 336 shares of FDMT on 2025-11-20. The shares were previously bought for an average price of USD 6.5602. The 4D Molecular Therapeutics Inc shares were sold for 57.6% higher than average price of previous purchases. This sale made a profit of USD 1,270 The average price that the ETF previously sold FDMT share for is USD 5.37104 so the ETF has sold 336 shares on 2025-11-20 at a higher price than the previous selling average. |
| CGEM - Cullinan Oncology LLC | SELL | -412 @ USD 8.72 | USD -3,593 | The ETF sold 412 shares of CGEM on 2025-11-20. The shares were previously bought for an average price of USD 7.9064. The Cullinan Oncology LLC shares were sold for 10.3% higher than average price of previous purchases. This sale made a profit of USD 335 The average price that the ETF previously sold CGEM share for is USD 10.152 which is higher than the selling price of USD 8.72 on 2025-11-20. |
| MRVI - Maravai Lifesciences Holdings Inc | SELL | -1,052 @ USD 3.42 | USD -3,598 | The ETF sold 1052 shares of MRVI on 2025-11-20. The shares were previously bought for an average price of USD 2.7464. The Maravai Lifesciences Holdings Inc shares were sold for 24.5% higher than average price of previous purchases. This sale made a profit of USD 709 The average price that the ETF previously sold MRVI share for is USD 3.71826 which is higher than the selling price of USD 3.42 on 2025-11-20. |
| PRTA - Prothena Corporation plc | SELL | -368 @ USD 10.05 | USD -3,698 | The ETF sold 368 shares of PRTA on 2025-11-20. The shares were previously bought for an average price of USD 9.05939. The Prothena Corporation plc shares were sold for 10.9% higher than average price of previous purchases. This sale made a profit of USD 365 The average price that the ETF previously sold PRTA share for is USD 12.4441 which is higher than the selling price of USD 10.05 on 2025-11-20. |
| RGNX - Regenxbio Inc | SELL | -352 @ USD 10.87 | USD -3,826 | The ETF sold 352 shares of RGNX on 2025-11-20. The shares were previously bought for an average price of USD 9.25492. The Regenxbio Inc shares were sold for 17.5% higher than average price of previous purchases. This sale made a profit of USD 569 The average price that the ETF previously sold RGNX share for is USD 7.7448 so the ETF has sold 352 shares on 2025-11-20 at a higher price than the previous selling average. |
| PACB - Pacific Biosciences of California | SELL | -2,132 @ USD 1.88 | USD -4,008 | The ETF sold 2132 shares of PACB on 2025-11-20. The shares were previously bought for an average price of USD 1.54626. The Pacific Biosciences of California shares were sold for 21.6% higher than average price of previous purchases. This sale made a profit of USD 712 The average price that the ETF previously sold PACB share for is USD 1.43682 so the ETF has sold 2132 shares on 2025-11-20 at a higher price than the previous selling average. |
| MGTX - MeiraGTx Holdings PLC | SELL | -540 @ USD 7.43 | USD -4,012 | The ETF sold 540 shares of MGTX on 2025-11-20. The shares were previously bought for an average price of USD 7.24673. The MeiraGTx Holdings PLC shares were sold for 2.5% higher than average price of previous purchases. This sale made a profit of USD 99 The average price that the ETF previously sold MGTX share for is USD 6.94809 so the ETF has sold 540 shares on 2025-11-20 at a higher price than the previous selling average. |
| KALV - Kalvista Pharmaceuticals Inc | SELL | -328 @ USD 13.02 | USD -4,271 | The ETF sold 328 shares of KALV on 2025-11-20. The shares were previously bought for an average price of USD 12.4527. The Kalvista Pharmaceuticals Inc shares were sold for 4.6% higher than average price of previous purchases. This sale made a profit of USD 186 The average price that the ETF previously sold KALV share for is USD 11.8592 so the ETF has sold 328 shares on 2025-11-20 at a higher price than the previous selling average. |
| PRME - Prime Medicine, Inc. Common Stock | SELL | -1,172 @ USD 3.69 | USD -4,325 | The ETF sold 1172 shares of PRME on 2025-11-20. The shares were previously bought for an average price of USD 4.50595. The Prime Medicine, Inc. Common Stock shares were sold for -18.1% lower than average price of previous purchases. This resulted in an overall loss of USD 956 The average price that the ETF previously sold PRME share for is USD 2.71258 so the ETF has sold 1172 shares on 2025-11-20 at a higher price than the previous selling average. |
| SPRY - Silverback Therapeutics Inc | SELL | -652 @ USD 6.73 | USD -4,388 | The ETF sold 652 shares of SPRY on 2025-11-20. The shares were previously bought for an average price of USD 13.422. The Silverback Therapeutics Inc shares were sold for -49.9% lower than average price of previous purchases. This resulted in an overall loss of USD 4,363 The average price that the ETF previously sold SPRY share for is USD 12.2245 which is higher than the selling price of USD 6.73 on 2025-11-20. |
| KROS - Keros Therapeutics Inc | SELL | -268 @ USD 16.82 | USD -4,508 | The ETF sold 268 shares of KROS on 2025-11-20. The shares were previously bought for an average price of USD 13.928. The Keros Therapeutics Inc shares were sold for 20.8% higher than average price of previous purchases. This sale made a profit of USD 775 The average price that the ETF previously sold KROS share for is USD 19.935 which is higher than the selling price of USD 16.82 on 2025-11-20. |
| GERN - Geron Corporation | SELL | -4,236 @ USD 1.1 | USD -4,660 | The ETF sold 4236 shares of GERN on 2025-11-20. The shares were previously bought for an average price of USD 1.4894. The Geron Corporation shares were sold for -26.1% lower than average price of previous purchases. This resulted in an overall loss of USD 1,649 The average price that the ETF previously sold GERN share for is USD 2.23732 which is higher than the selling price of USD 1.1 on 2025-11-20. |
| REPL - Replimune Group Inc | SELL | -536 @ USD 9.01 | USD -4,829 | The ETF sold 536 shares of REPL on 2025-11-20. The shares were previously bought for an average price of USD 8.85908. The Replimune Group Inc shares were sold for 1.7% higher than average price of previous purchases. This sale made a profit of USD 81 The average price that the ETF previously sold REPL share for is USD 10.0103 which is higher than the selling price of USD 9.01 on 2025-11-20. |
| VIR - Vir Biotechnology Inc | SELL | -924 @ USD 5.56 | USD -5,137 | The ETF sold 924 shares of VIR on 2025-11-20. The shares were previously bought for an average price of USD 5.81465. The Vir Biotechnology Inc shares were sold for -4.4% lower than average price of previous purchases. This resulted in an overall loss of USD 235 The average price that the ETF previously sold VIR share for is USD 6.39153 which is higher than the selling price of USD 5.56 on 2025-11-20. |
| VIR - Vidrala S.A | SELL | -924 @ USD 5.56 | USD -5,137 | The ETF sold 924 shares of VIR on 2025-11-20. The shares were previously bought for an average price of USD 5.81465. The Vidrala S.A shares were sold for -4.4% lower than average price of previous purchases. This resulted in an overall loss of USD 235 The average price that the ETF previously sold VIR share for is USD 6.39153 which is higher than the selling price of USD 5.56 on 2025-11-20. |
| IOVA - Iovance Biotherapeutics Inc | SELL | -2,372 @ USD 2.18 | USD -5,171 | The ETF sold 2372 shares of IOVA on 2025-11-20. The shares were previously bought for an average price of USD 2.4364. The Iovance Biotherapeutics Inc shares were sold for -10.5% lower than average price of previous purchases. This resulted in an overall loss of USD 608 The average price that the ETF previously sold IOVA share for is USD 5.0707 which is higher than the selling price of USD 2.18 on 2025-11-20. |
| ARVN - Arvinas Inc | SELL | -476 @ USD 11.02 | USD -5,246 | The ETF sold 476 shares of ARVN on 2025-11-20. The shares were previously bought for an average price of USD 8.90576. The Arvinas Inc shares were sold for 23.7% higher than average price of previous purchases. This sale made a profit of USD 1,006 The average price that the ETF previously sold ARVN share for is USD 12.4219 which is higher than the selling price of USD 11.02 on 2025-11-20. |
| SVRA - Savara Inc | SELL | -1,152 @ USD 4.67 | USD -5,380 | The ETF sold 1152 shares of SVRA on 2025-11-20. The shares were previously bought for an average price of USD 2.8915. The Savara Inc shares were sold for 61.5% higher than average price of previous purchases. This sale made a profit of USD 2,049 The average price that the ETF previously sold SVRA share for is USD 2.82857 so the ETF has sold 1152 shares on 2025-11-20 at a higher price than the previous selling average. |
| PAHC - Phibro Animal Health Corporation | SELL | -132 @ USD 40.81 | USD -5,387 | The ETF sold 132 shares of PAHC on 2025-11-20. The shares were previously bought for an average price of USD 29.2193. The Phibro Animal Health Corporation shares were sold for 39.7% higher than average price of previous purchases. This sale made a profit of USD 1,530 The average price that the ETF previously sold PAHC share for is USD 25.3872 so the ETF has sold 132 shares on 2025-11-20 at a higher price than the previous selling average. |
| ABUS - Arbutus Biopharma Corp | SELL | -1,304 @ USD 4.2 | USD -5,477 | The ETF sold 1304 shares of ABUS on 2025-11-20. The shares were previously bought for an average price of USD 3.67721. The Arbutus Biopharma Corp shares were sold for 14.2% higher than average price of previous purchases. This sale made a profit of USD 682 The average price that the ETF previously sold ABUS share for is USD 3.3363 so the ETF has sold 1304 shares on 2025-11-20 at a higher price than the previous selling average. |
| DAWN - Day One Biopharmaceuticals Inc | SELL | -676 @ USD 8.29 | USD -5,604 | The ETF sold 676 shares of DAWN on 2025-11-20. The shares were previously bought for an average price of USD 7.48373. The Day One Biopharmaceuticals Inc shares were sold for 10.8% higher than average price of previous purchases. This sale made a profit of USD 545 The average price that the ETF previously sold DAWN share for is USD 9.31651 which is higher than the selling price of USD 8.29 on 2025-11-20. |
| MNMD - Mind Medicine Inc | SELL | -516 @ USD 10.88 | USD -5,614 | The ETF sold 516 shares of MNMD on 2025-11-20. The shares were previously bought for an average price of USD 8.72776. The Mind Medicine Inc shares were sold for 24.7% higher than average price of previous purchases. This sale made a profit of USD 1,111 The average price that the ETF previously sold MNMD share for is USD 7.08053 so the ETF has sold 516 shares on 2025-11-20 at a higher price than the previous selling average. |
| ERAS - Erasca Inc | SELL | -2,028 @ USD 2.78 | USD -5,638 | The ETF sold 2028 shares of ERAS on 2025-11-20. The shares were previously bought for an average price of USD 1.71399. The Erasca Inc shares were sold for 62.2% higher than average price of previous purchases. This sale made a profit of USD 2,162 The average price that the ETF previously sold ERAS share for is USD 1.96763 so the ETF has sold 2028 shares on 2025-11-20 at a higher price than the previous selling average. |
| SANA - Sana Biotechnology Inc | SELL | -1,752 @ USD 3.23 | USD -5,659 | The ETF sold 1752 shares of SANA on 2025-11-20. The shares were previously bought for an average price of USD 3.23803. The Sana Biotechnology Inc shares were sold for -0.2% lower than average price of previous purchases. This resulted in an overall loss of USD 14 The average price that the ETF previously sold SANA share for is USD 2.38969 so the ETF has sold 1752 shares on 2025-11-20 at a higher price than the previous selling average. |
| NTLA - Intellia Therapeutics Inc | SELL | -724 @ USD 8.04 | USD -5,821 | The ETF sold 724 shares of NTLA on 2025-11-20. The shares were previously bought for an average price of USD 12.2519. The Intellia Therapeutics Inc shares were sold for -34.4% lower than average price of previous purchases. This resulted in an overall loss of USD 3,049 The average price that the ETF previously sold NTLA share for is USD 11.2476 which is higher than the selling price of USD 8.04 on 2025-11-20. |
| TBPH - Theravance Biopharma Inc | SELL | -336 @ USD 17.9 | USD -6,014 | The ETF sold 336 shares of TBPH on 2025-11-20. The shares were previously bought for an average price of USD 12.0755. The Theravance Biopharma Inc shares were sold for 48.2% higher than average price of previous purchases. This sale made a profit of USD 1,957 The average price that the ETF previously sold TBPH share for is USD 10.9514 so the ETF has sold 336 shares on 2025-11-20 at a higher price than the previous selling average. |
| FTRE - Fortrea Holdings Inc. | SELL | -604 @ USD 10.04 | USD -6,064 | The ETF sold 604 shares of FTRE on 2025-11-20. The shares were previously bought for an average price of USD 6.80192. The Fortrea Holdings Inc. shares were sold for 47.6% higher than average price of previous purchases. This sale made a profit of USD 1,956 The average price that the ETF previously sold FTRE share for is USD 12.8178 which is higher than the selling price of USD 10.04 on 2025-11-20. |
| EYPT - Eyepoint Pharmaceuticals Inc | SELL | -460 @ USD 13.64 | USD -6,274 | The ETF sold 460 shares of EYPT on 2025-11-20. The shares were previously bought for an average price of USD 8.95734. The Eyepoint Pharmaceuticals Inc shares were sold for 52.3% higher than average price of previous purchases. This sale made a profit of USD 2,154 The average price that the ETF previously sold EYPT share for is USD 9.1286 so the ETF has sold 460 shares on 2025-11-20 at a higher price than the previous selling average. |
| ZLAB - Zai Lab Ltd | SELL | -316 @ USD 20.21 | USD -6,386 | The ETF sold 316 shares of ZLAB on 2025-11-20. The shares were previously bought for an average price of USD 33.5198. The Zai Lab Ltd shares were sold for -39.7% lower than average price of previous purchases. This resulted in an overall loss of USD 4,206 The average price that the ETF previously sold ZLAB share for is USD 31.229 which is higher than the selling price of USD 20.21 on 2025-11-20. |
| TNGX - Tango Therapeutics Inc | SELL | -740 @ USD 8.9 | USD -6,586 | The ETF sold 740 shares of TNGX on 2025-11-20. The shares were previously bought for an average price of USD 6.28576. The Tango Therapeutics Inc shares were sold for 41.6% higher than average price of previous purchases. This sale made a profit of USD 1,935 The average price that the ETF previously sold TNGX share for is USD 3.36961 so the ETF has sold 740 shares on 2025-11-20 at a higher price than the previous selling average. |
| KURA - Kura Oncology Inc | SELL | -600 @ USD 10.98 | USD -6,588 | The ETF sold 600 shares of KURA on 2025-11-20. The shares were previously bought for an average price of USD 7.41785. The Kura Oncology Inc shares were sold for 48.0% higher than average price of previous purchases. This sale made a profit of USD 2,137 The average price that the ETF previously sold KURA share for is USD 8.77445 so the ETF has sold 600 shares on 2025-11-20 at a higher price than the previous selling average. |
| NVAX - Novavax Inc | SELL | -1,080 @ USD 6.22 | USD -6,718 | The ETF sold 1080 shares of NVAX on 2025-11-20. The shares were previously bought for an average price of USD 7.33655. The Novavax Inc shares were sold for -15.2% lower than average price of previous purchases. This resulted in an overall loss of USD 1,206 The average price that the ETF previously sold NVAX share for is USD 7.68446 which is higher than the selling price of USD 6.22 on 2025-11-20. |
| NVAX - Hana Microelectronics Public Company Limited | SELL | -1,080 @ USD 6.22 | USD -6,718 | The ETF sold 1080 shares of NVAX on 2025-11-20. The shares were previously bought for an average price of USD 7.33655. The Hana Microelectronics Public Company Limited shares were sold for -15.2% lower than average price of previous purchases. This resulted in an overall loss of USD 1,206 The average price that the ETF previously sold NVAX share for is USD 7.68446 which is higher than the selling price of USD 6.22 on 2025-11-20. |
| PCRX - Pacira BioSciences, Inc. | SELL | -296 @ USD 22.8 | USD -6,749 | The ETF sold 296 shares of PCRX on 2025-11-20. The shares were previously bought for an average price of USD 23.8015. The Pacira BioSciences, Inc. shares were sold for -4.2% lower than average price of previous purchases. This resulted in an overall loss of USD 296 The average price that the ETF previously sold PCRX share for is USD 21.9605 so the ETF has sold 296 shares on 2025-11-20 at a higher price than the previous selling average. |
| ABCL - Abcellera Biologics Inc | SELL | -1,988 @ USD 3.41 | USD -6,779 | The ETF sold 1988 shares of ABCL on 2025-11-20. The shares were previously bought for an average price of USD 3.91066. The Abcellera Biologics Inc shares were sold for -12.8% lower than average price of previous purchases. This resulted in an overall loss of USD 995 The average price that the ETF previously sold ABCL share for is USD 3.18402 so the ETF has sold 1988 shares on 2025-11-20 at a higher price than the previous selling average. |
| GRFS - Grifols SA ADR | SELL | -812 @ USD 8.43 | USD -6,845 | The ETF sold 812 shares of GRFS on 2025-11-20. The shares were previously bought for an average price of USD 9.38219. The Grifols SA ADR shares were sold for -10.1% lower than average price of previous purchases. This resulted in an overall loss of USD 773 The average price that the ETF previously sold GRFS share for is USD 8.45656 which is higher than the selling price of USD 8.43 on 2025-11-20. |
| CSTL - Castle Biosciences Inc | SELL | -192 @ USD 35.72 | USD -6,858 | The ETF sold 192 shares of CSTL on 2025-11-20. The shares were previously bought for an average price of USD 22.2634. The Castle Biosciences Inc shares were sold for 60.4% higher than average price of previous purchases. This sale made a profit of USD 2,584 The average price that the ETF previously sold CSTL share for is USD 23.2586 so the ETF has sold 192 shares on 2025-11-20 at a higher price than the previous selling average. |
| PHAT - Phathom Pharmaceuticals Inc | SELL | -480 @ USD 14.36 | USD -6,893 | The ETF sold 480 shares of PHAT on 2025-11-20. The shares were previously bought for an average price of USD 9.2816. The Phathom Pharmaceuticals Inc shares were sold for 54.7% higher than average price of previous purchases. This sale made a profit of USD 2,438 The average price that the ETF previously sold PHAT share for is USD 7.47171 so the ETF has sold 480 shares on 2025-11-20 at a higher price than the previous selling average. |
| ANAB - AnaptysBio Inc | SELL | -184 @ USD 37.66 | USD -6,929 | The ETF sold 184 shares of ANAB on 2025-11-20. The shares were previously bought for an average price of USD 24.7. The AnaptysBio Inc shares were sold for 52.5% higher than average price of previous purchases. This sale made a profit of USD 2,385 The average price that the ETF previously sold ANAB share for is USD 18.8887 so the ETF has sold 184 shares on 2025-11-20 at a higher price than the previous selling average. |
| AGIO - Agios Pharm | SELL | -288 @ USD 24.57 | USD -7,076 | The ETF sold 288 shares of AGIO on 2025-11-20. The shares were previously bought for an average price of USD 36.3841. The Agios Pharm shares were sold for -32.5% lower than average price of previous purchases. This resulted in an overall loss of USD 3,402 The average price that the ETF previously sold AGIO share for is USD 36.1074 which is higher than the selling price of USD 24.57 on 2025-11-20. |
| TSHA - Taysha Gene Therapies Inc | SELL | -1,816 @ USD 3.99 | USD -7,246 | The ETF sold 1816 shares of TSHA on 2025-11-20. The shares were previously bought for an average price of USD 2.92548. The Taysha Gene Therapies Inc shares were sold for 36.4% higher than average price of previous purchases. This sale made a profit of USD 1,933 The average price that the ETF previously sold TSHA share for is USD 2.0192 so the ETF has sold 1816 shares on 2025-11-20 at a higher price than the previous selling average. |
| WVE - Wave Life Sciences Ltd | SELL | -1,084 @ USD 6.755 | USD -7,322 | The ETF sold 1084 shares of WVE on 2025-11-20. The shares were previously bought for an average price of USD 8.37281. The Wave Life Sciences Ltd shares were sold for -19.3% lower than average price of previous purchases. This resulted in an overall loss of USD 1,754 The average price that the ETF previously sold WVE share for is USD 8.67213 which is higher than the selling price of USD 6.755 on 2025-11-20. |
| RLAY - Relay Therapeutics Inc | SELL | -1,148 @ USD 6.38 | USD -7,324 | The ETF sold 1148 shares of RLAY on 2025-11-20. The shares were previously bought for an average price of USD 4.2441. The Relay Therapeutics Inc shares were sold for 50.3% higher than average price of previous purchases. This sale made a profit of USD 2,452 The average price that the ETF previously sold RLAY share for is USD 3.91088 so the ETF has sold 1148 shares on 2025-11-20 at a higher price than the previous selling average. |
| XNCR - Xencor Inc | SELL | -472 @ USD 15.575 | USD -7,351 | The ETF sold 472 shares of XNCR on 2025-11-20. The shares were previously bought for an average price of USD 11.3346. The Xencor Inc shares were sold for 37.4% higher than average price of previous purchases. This sale made a profit of USD 2,001 The average price that the ETF previously sold XNCR share for is USD 12.8197 so the ETF has sold 472 shares on 2025-11-20 at a higher price than the previous selling average. |
| ORIC - Oric Pharmaceuticals Inc | SELL | -644 @ USD 11.48 | USD -7,393 | The ETF sold 644 shares of ORIC on 2025-11-20. The shares were previously bought for an average price of USD 10.5525. The Oric Pharmaceuticals Inc shares were sold for 8.8% higher than average price of previous purchases. This sale made a profit of USD 597 The average price that the ETF previously sold ORIC share for is USD 8.12503 so the ETF has sold 644 shares on 2025-11-20 at a higher price than the previous selling average. |
| XERS - Xeris Pharmaceuticals Inc | SELL | -1,104 @ USD 6.84 | USD -7,551 | The ETF sold 1104 shares of XERS on 2025-11-20. The shares were previously bought for an average price of USD 6.09787. The Xeris Pharmaceuticals Inc shares were sold for 12.2% higher than average price of previous purchases. This sale made a profit of USD 819 The average price that the ETF previously sold XERS share for is USD 4.72691 so the ETF has sold 1104 shares on 2025-11-20 at a higher price than the previous selling average. |
| CVAC - CureVac NV | SELL | -1,496 @ USD 5.12 | USD -7,660 | The ETF sold 1496 shares of CVAC on 2025-11-20. The shares were previously bought for an average price of USD 4.86295. The CureVac NV shares were sold for 5.3% higher than average price of previous purchases. This sale made a profit of USD 385 The average price that the ETF previously sold CVAC share for is USD 3.65091 so the ETF has sold 1496 shares on 2025-11-20 at a higher price than the previous selling average. |
| AMPH - Amphastar P | SELL | -308 @ USD 25.36 | USD -7,811 | The ETF sold 308 shares of AMPH on 2025-11-20. The shares were previously bought for an average price of USD 25.4814. The Amphastar P shares were sold for -0.5% lower than average price of previous purchases. This resulted in an overall loss of USD 37 The average price that the ETF previously sold AMPH share for is USD 31.5968 which is higher than the selling price of USD 25.36 on 2025-11-20. |
| URGN - UroGen Pharma Ltd | SELL | -316 @ USD 24.84 | USD -7,849 | The ETF sold 316 shares of URGN on 2025-11-20. The shares were previously bought for an average price of USD 15.1315. The UroGen Pharma Ltd shares were sold for 64.2% higher than average price of previous purchases. This sale made a profit of USD 3,068 The average price that the ETF previously sold URGN share for is USD 12.6302 so the ETF has sold 316 shares on 2025-11-20 at a higher price than the previous selling average. |
| PGEN - Precigen Inc | SELL | -2,024 @ USD 3.9 | USD -7,894 | The ETF sold 2024 shares of PGEN on 2025-11-20. The shares were previously bought for an average price of USD 2.41043. The Precigen Inc shares were sold for 61.8% higher than average price of previous purchases. This sale made a profit of USD 3,015 The average price that the ETF previously sold PGEN share for is USD 1.6059 so the ETF has sold 2024 shares on 2025-11-20 at a higher price than the previous selling average. |
| AMLX - Amylyx Pharmaceuticals Inc | SELL | -592 @ USD 13.57 | USD -8,033 | The ETF sold 592 shares of AMLX on 2025-11-20. The shares were previously bought for an average price of USD 7.18795. The Amylyx Pharmaceuticals Inc shares were sold for 88.8% higher than average price of previous purchases. This sale made a profit of USD 3,778 The average price that the ETF previously sold AMLX share for is USD 7.6564 so the ETF has sold 592 shares on 2025-11-20 at a higher price than the previous selling average. |
| NRIX - Nurix Therapeutics Inc | SELL | -532 @ USD 15.33 | USD -8,156 | The ETF sold 532 shares of NRIX on 2025-11-20. The shares were previously bought for an average price of USD 12.0996. The Nurix Therapeutics Inc shares were sold for 26.7% higher than average price of previous purchases. This sale made a profit of USD 1,719 The average price that the ETF previously sold NRIX share for is USD 14.1584 so the ETF has sold 532 shares on 2025-11-20 at a higher price than the previous selling average. |
| GMAB - Genmab AS | SELL | -276 @ USD 30.04 | USD -8,291 | The ETF sold 276 shares of GMAB on 2025-11-20. The shares were previously bought for an average price of USD 23.7448. The Genmab AS shares were sold for 26.5% higher than average price of previous purchases. This sale made a profit of USD 1,737 The average price that the ETF previously sold GMAB share for is USD 22.5215 so the ETF has sold 276 shares on 2025-11-20 at a higher price than the previous selling average. |
| ELVN - Enliven Therapeutics Inc. | SELL | -392 @ USD 21.27 | USD -8,338 | The ETF sold 392 shares of ELVN on 2025-11-20. The shares were previously bought for an average price of USD 20.4628. The Enliven Therapeutics Inc. shares were sold for 3.9% higher than average price of previous purchases. This sale made a profit of USD 316 The average price that the ETF previously sold ELVN share for is USD 21.3899 which is higher than the selling price of USD 21.27 on 2025-11-20. |
| DVAX - Dynavax Technologies Corporation | SELL | -780 @ USD 10.8 | USD -8,424 | The ETF sold 780 shares of DVAX on 2025-11-20. The shares were previously bought for an average price of USD 10.5249. The Dynavax Technologies Corporation shares were sold for 2.6% higher than average price of previous purchases. This sale made a profit of USD 215 The average price that the ETF previously sold DVAX share for is USD 11.9228 which is higher than the selling price of USD 10.8 on 2025-11-20. |
| NVCR - Novocure Ltd | SELL | -740 @ USD 11.46 | USD -8,480 | The ETF sold 740 shares of NVCR on 2025-11-20. The shares were previously bought for an average price of USD 16.4207. The Novocure Ltd shares were sold for -30.2% lower than average price of previous purchases. This resulted in an overall loss of USD 3,671 The average price that the ETF previously sold NVCR share for is USD 19.9113 which is higher than the selling price of USD 11.46 on 2025-11-20. |
| INVA - Innoviva Inc | SELL | -416 @ USD 21.16 | USD -8,803 | The ETF sold 416 shares of INVA on 2025-11-20. The shares were previously bought for an average price of USD 19.0589. The Innoviva Inc shares were sold for 11.0% higher than average price of previous purchases. This sale made a profit of USD 874 The average price that the ETF previously sold INVA share for is USD 18.0969 so the ETF has sold 416 shares on 2025-11-20 at a higher price than the previous selling average. |
| ARDX - Ardelyx Inc | SELL | -1,600 @ USD 5.55 | USD -8,880 | The ETF sold 1600 shares of ARDX on 2025-11-20. The shares were previously bought for an average price of USD 4.68207. The Ardelyx Inc shares were sold for 18.5% higher than average price of previous purchases. This sale made a profit of USD 1,389 The average price that the ETF previously sold ARDX share for is USD 5.2081 so the ETF has sold 1600 shares on 2025-11-20 at a higher price than the previous selling average. |
| COLL - Collegium Pharmaceutical Inc | SELL | -208 @ USD 43.95 | USD -9,142 | The ETF sold 208 shares of COLL on 2025-11-20. The shares were previously bought for an average price of USD 32.355. The Collegium Pharmaceutical Inc shares were sold for 35.8% higher than average price of previous purchases. This sale made a profit of USD 2,412 The average price that the ETF previously sold COLL share for is USD 30.6791 so the ETF has sold 208 shares on 2025-11-20 at a higher price than the previous selling average. |
| HROW - Harrow Health Inc | SELL | -244 @ USD 37.66 | USD -9,189 | The ETF sold 244 shares of HROW on 2025-11-20. The shares were previously bought for an average price of USD 33.666. The Harrow Health Inc shares were sold for 11.9% higher than average price of previous purchases. This sale made a profit of USD 975 The average price that the ETF previously sold HROW share for is USD 33.2199 so the ETF has sold 244 shares on 2025-11-20 at a higher price than the previous selling average. |
| SYRE - Spyre Therapeutics Inc. | SELL | -396 @ USD 23.47 | USD -9,294 | The ETF sold 396 shares of SYRE on 2025-11-20. The shares were previously bought for an average price of USD 17.8181. The Spyre Therapeutics Inc. shares were sold for 31.7% higher than average price of previous purchases. This sale made a profit of USD 2,238 The average price that the ETF previously sold SYRE share for is USD 16.4541 so the ETF has sold 396 shares on 2025-11-20 at a higher price than the previous selling average. |
| SNDX - Syndax Pharmaceuticals Inc | SELL | -572 @ USD 17.05 | USD -9,753 | The ETF sold 572 shares of SNDX on 2025-11-20. The shares were previously bought for an average price of USD 11.9113. The Syndax Pharmaceuticals Inc shares were sold for 43.1% higher than average price of previous purchases. This sale made a profit of USD 2,939 The average price that the ETF previously sold SNDX share for is USD 13.286 so the ETF has sold 572 shares on 2025-11-20 at a higher price than the previous selling average. |
| BCRX - BioCryst Pharmaceuticals Inc | SELL | -1,392 @ USD 7.03 | USD -9,786 | The ETF sold 1392 shares of BCRX on 2025-11-20. The shares were previously bought for an average price of USD 8.24065. The BioCryst Pharmaceuticals Inc shares were sold for -14.7% lower than average price of previous purchases. This resulted in an overall loss of USD 1,685 The average price that the ETF previously sold BCRX share for is USD 7.57239 which is higher than the selling price of USD 7.03 on 2025-11-20. |
| OLMA - Olema Pharmaceuticals Inc | SELL | -448 @ USD 22.01 | USD -9,860 | The ETF sold 448 shares of OLMA on 2025-11-20. The shares were previously bought for an average price of USD 6.01396. The Olema Pharmaceuticals Inc shares were sold for 266.0% higher than average price of previous purchases. This sale made a profit of USD 7,166 The average price that the ETF previously sold OLMA share for is USD 6.27404 so the ETF has sold 448 shares on 2025-11-20 at a higher price than the previous selling average. |
| MNKD - MannKind Corp | SELL | -2,036 @ USD 4.97 | USD -10,119 | The ETF sold 2036 shares of MNKD on 2025-11-20. The shares were previously bought for an average price of USD 4.73178. The MannKind Corp shares were sold for 5.0% higher than average price of previous purchases. This sale made a profit of USD 485 The average price that the ETF previously sold MNKD share for is USD 5.56 which is higher than the selling price of USD 4.97 on 2025-11-20. |
| QURE - Uniqure NV | SELL | -364 @ USD 27.9 | USD -10,156 | The ETF sold 364 shares of QURE on 2025-11-20. The shares were previously bought for an average price of USD 23.2227. The Uniqure NV shares were sold for 20.1% higher than average price of previous purchases. This sale made a profit of USD 1,703 The average price that the ETF previously sold QURE share for is USD 21.9734 so the ETF has sold 364 shares on 2025-11-20 at a higher price than the previous selling average. |
| STOK - Stoke Therapeutics Inc | SELL | -368 @ USD 27.93 | USD -10,278 | The ETF sold 368 shares of STOK on 2025-11-20. The shares were previously bought for an average price of USD 16.3612. The Stoke Therapeutics Inc shares were sold for 70.7% higher than average price of previous purchases. This sale made a profit of USD 4,257 The average price that the ETF previously sold STOK share for is USD 10.9138 so the ETF has sold 368 shares on 2025-11-20 at a higher price than the previous selling average. |
| TWST - Twist Bioscience Corp | SELL | -400 @ USD 26.07 | USD -10,428 | The ETF sold 400 shares of TWST on 2025-11-20. The shares were previously bought for an average price of USD 35.8053. The Twist Bioscience Corp shares were sold for -27.2% lower than average price of previous purchases. This resulted in an overall loss of USD 3,894 The average price that the ETF previously sold TWST share for is USD 38.6709 which is higher than the selling price of USD 26.07 on 2025-11-20. |
| IMCR - Immunocore Holdings Ltd | SELL | -272 @ USD 39.01 | USD -10,611 | The ETF sold 272 shares of IMCR on 2025-11-20. The shares were previously bought for an average price of USD 32.992. The Immunocore Holdings Ltd shares were sold for 18.2% higher than average price of previous purchases. This sale made a profit of USD 1,637 The average price that the ETF previously sold IMCR share for is USD 30.533 so the ETF has sold 272 shares on 2025-11-20 at a higher price than the previous selling average. |
| SRPT - Sarepta Therapeutics Inc | SELL | -648 @ USD 16.48 | USD -10,679 | The ETF sold 648 shares of SRPT on 2025-11-20. The shares were previously bought for an average price of USD 33.1669. The Sarepta Therapeutics Inc shares were sold for -50.3% lower than average price of previous purchases. This resulted in an overall loss of USD 10,813 The average price that the ETF previously sold SRPT share for is USD 76.1232 which is higher than the selling price of USD 16.48 on 2025-11-20. |
| RXRX - Recursion Pharmaceuticals Inc | SELL | -2,884 @ USD 3.85 | USD -11,103 | The ETF sold 2884 shares of RXRX on 2025-11-20. The shares were previously bought for an average price of USD 5.71897. The Recursion Pharmaceuticals Inc shares were sold for -32.7% lower than average price of previous purchases. This resulted in an overall loss of USD 5,390 The average price that the ETF previously sold RXRX share for is USD 5.59508 which is higher than the selling price of USD 3.85 on 2025-11-20. |
| ANIP - ANI Pharmaceuticals Inc | SELL | -144 @ USD 78.52 | USD -11,307 | The ETF sold 144 shares of ANIP on 2025-11-20. The shares were previously bought for an average price of USD 72.1893. The ANI Pharmaceuticals Inc shares were sold for 8.8% higher than average price of previous purchases. This sale made a profit of USD 912 The average price that the ETF previously sold ANIP share for is USD 68.008 so the ETF has sold 144 shares on 2025-11-20 at a higher price than the previous selling average. |
| JANX - Janux Therapeutics Inc | SELL | -396 @ USD 28.59 | USD -11,322 | The ETF sold 396 shares of JANX on 2025-11-20. The shares were previously bought for an average price of USD 27.733. The Janux Therapeutics Inc shares were sold for 3.1% higher than average price of previous purchases. This sale made a profit of USD 339 The average price that the ETF previously sold JANX share for is USD 36.6545 which is higher than the selling price of USD 28.59 on 2025-11-20. |
| VERA - Vera Therapeutics Inc | SELL | -420 @ USD 27.87 | USD -11,705 | The ETF sold 420 shares of VERA on 2025-11-20. The shares were previously bought for an average price of USD 26.8909. The Vera Therapeutics Inc shares were sold for 3.6% higher than average price of previous purchases. This sale made a profit of USD 411 The average price that the ETF previously sold VERA share for is USD 28.5651 which is higher than the selling price of USD 27.87 on 2025-11-20. |
| KNSA - Kiniksa Pharmaceuticals Ltd | SELL | -292 @ USD 41.49 | USD -12,115 | The ETF sold 292 shares of KNSA on 2025-11-20. The shares were previously bought for an average price of USD 30.3382. The Kiniksa Pharmaceuticals Ltd shares were sold for 36.8% higher than average price of previous purchases. This sale made a profit of USD 3,256 The average price that the ETF previously sold KNSA share for is USD 22.947 so the ETF has sold 292 shares on 2025-11-20 at a higher price than the previous selling average. |
| ZYME - Zymeworks Inc. Common Stock | SELL | -512 @ USD 23.82 | USD -12,196 | The ETF sold 512 shares of ZYME on 2025-11-20. The shares were previously bought for an average price of USD 14.7748. The Zymeworks Inc. Common Stock shares were sold for 61.2% higher than average price of previous purchases. This sale made a profit of USD 4,631 The average price that the ETF previously sold ZYME share for is USD 13.6339 so the ETF has sold 512 shares on 2025-11-20 at a higher price than the previous selling average. |
| VCEL - Vericel Corp Ord | SELL | -332 @ USD 37.85 | USD -12,566 | The ETF sold 332 shares of VCEL on 2025-11-20. The shares were previously bought for an average price of USD 40.6783. The Vericel Corp Ord shares were sold for -7.0% lower than average price of previous purchases. This resulted in an overall loss of USD 939 The average price that the ETF previously sold VCEL share for is USD 45.0154 which is higher than the selling price of USD 37.85 on 2025-11-20. |
| TXG - 10X Genomics Inc | SELL | -764 @ USD 16.46 | USD -12,575 | The ETF sold 764 shares of TXG on 2025-11-20. The shares were previously bought for an average price of USD 12.3058. The 10X Genomics Inc shares were sold for 33.8% higher than average price of previous purchases. This sale made a profit of USD 3,174 The average price that the ETF previously sold TXG share for is USD 10.4035 so the ETF has sold 764 shares on 2025-11-20 at a higher price than the previous selling average. |
| TXG - Terex Corporation | SELL | -764 @ USD 16.46 | USD -12,575 | The ETF sold 764 shares of TXG on 2025-11-20. The shares were previously bought for an average price of USD 12.3058. The Terex Corporation shares were sold for 33.8% higher than average price of previous purchases. This sale made a profit of USD 3,174 The average price that the ETF previously sold TXG share for is USD 10.4035 so the ETF has sold 764 shares on 2025-11-20 at a higher price than the previous selling average. |
| HRMY - Harmony Biosciences Holdings | SELL | -380 @ USD 33.39 | USD -12,688 | The ETF sold 380 shares of HRMY on 2025-11-20. The shares were previously bought for an average price of USD 31.9599. The Harmony Biosciences Holdings shares were sold for 4.5% higher than average price of previous purchases. This sale made a profit of USD 543 The average price that the ETF previously sold HRMY share for is USD 32.0152 so the ETF has sold 380 shares on 2025-11-20 at a higher price than the previous selling average. |
| IBRX - Immunitybio Inc | SELL | -6,348 @ USD 2.02 | USD -12,823 | The ETF sold 6348 shares of IBRX on 2025-11-20. The shares were previously bought for an average price of USD 2.73087. The Immunitybio Inc shares were sold for -26.0% lower than average price of previous purchases. This resulted in an overall loss of USD 4,513 The average price that the ETF previously sold IBRX share for is USD 3.05172 which is higher than the selling price of USD 2.02 on 2025-11-20. |
| AUPH - Aurinia Pharmaceuticals Inc | SELL | -872 @ USD 15.14 | USD -13,202 | The ETF sold 872 shares of AUPH on 2025-11-20. The shares were previously bought for an average price of USD 9.46972. The Aurinia Pharmaceuticals Inc shares were sold for 59.9% higher than average price of previous purchases. This sale made a profit of USD 4,944 The average price that the ETF previously sold AUPH share for is USD 9.44961 so the ETF has sold 872 shares on 2025-11-20 at a higher price than the previous selling average. |
| GPCR - Structure Therapeutics Inc. American Depositary Shares | SELL | -392 @ USD 34.34 | USD -13,461 | The ETF sold 392 shares of GPCR on 2025-11-20. The shares were previously bought for an average price of USD 23.6556. The Structure Therapeutics Inc. American Depositary Shares shares were sold for 45.2% higher than average price of previous purchases. This sale made a profit of USD 4,188 The average price that the ETF previously sold GPCR share for is USD 23.9281 so the ETF has sold 392 shares on 2025-11-20 at a higher price than the previous selling average. |
| OCUL - Ocular Therapeutix Inc | SELL | -1,152 @ USD 11.72 | USD -13,501 | The ETF sold 1152 shares of OCUL on 2025-11-20. The shares were previously bought for an average price of USD 10.0667. The Ocular Therapeutix Inc shares were sold for 16.4% higher than average price of previous purchases. This sale made a profit of USD 1,905 The average price that the ETF previously sold OCUL share for is USD 8.5584 so the ETF has sold 1152 shares on 2025-11-20 at a higher price than the previous selling average. |
| BEAM - Beam Therapeutics Inc | SELL | -668 @ USD 20.6 | USD -13,761 | The ETF sold 668 shares of BEAM on 2025-11-20. The shares were previously bought for an average price of USD 20.6453. The Beam Therapeutics Inc shares were sold for -0.2% lower than average price of previous purchases. This resulted in an overall loss of USD 30 The average price that the ETF previously sold BEAM share for is USD 22.7165 which is higher than the selling price of USD 20.6 on 2025-11-20. |
| AVDL - Avadel Pharmaceuticals PLC | SELL | -640 @ USD 22.94 | USD -14,682 | The ETF sold 640 shares of AVDL on 2025-11-20. The shares were previously bought for an average price of USD 11.5303. The Avadel Pharmaceuticals PLC shares were sold for 99.0% higher than average price of previous purchases. This sale made a profit of USD 7,302 The average price that the ETF previously sold AVDL share for is USD 10.9479 so the ETF has sold 640 shares on 2025-11-20 at a higher price than the previous selling average. |
| TERN - Tern Plc | SELL | -580 @ USD 26.11 | USD -15,144 | The ETF sold 580 shares of TERN on 2025-11-20. The shares were previously bought for an average price of USD 6.35718. The Tern Plc shares were sold for 310.7% higher than average price of previous purchases. This sale made a profit of USD 11,457 The average price that the ETF previously sold TERN share for is USD 5.46202 so the ETF has sold 580 shares on 2025-11-20 at a higher price than the previous selling average. |
| LEGN - Legend Biotech Corp | SELL | -560 @ USD 27.53 | USD -15,417 | The ETF sold 560 shares of LEGN on 2025-11-20. The shares were previously bought for an average price of USD 34.4961. The Legend Biotech Corp shares were sold for -20.2% lower than average price of previous purchases. This resulted in an overall loss of USD 3,901 The average price that the ETF previously sold LEGN share for is USD 34.9029 which is higher than the selling price of USD 27.53 on 2025-11-20. |
| EWTX - Edgewise Therapeutics Inc | SELL | -696 @ USD 22.25 | USD -15,486 | The ETF sold 696 shares of EWTX on 2025-11-20. The shares were previously bought for an average price of USD 16.1366. The Edgewise Therapeutics Inc shares were sold for 37.9% higher than average price of previous purchases. This sale made a profit of USD 4,255 The average price that the ETF previously sold EWTX share for is USD 21.8748 so the ETF has sold 696 shares on 2025-11-20 at a higher price than the previous selling average. |
| ADPT - Adaptive Biotechnologies Corp | SELL | -1,008 @ USD 16.32 | USD -16,451 | The ETF sold 1008 shares of ADPT on 2025-11-20. The shares were previously bought for an average price of USD 11.9504. The Adaptive Biotechnologies Corp shares were sold for 36.6% higher than average price of previous purchases. This sale made a profit of USD 4,405 The average price that the ETF previously sold ADPT share for is USD 7.90658 so the ETF has sold 1008 shares on 2025-11-20 at a higher price than the previous selling average. |
| DNLI - Denali Therapeutics Inc | SELL | -964 @ USD 17.16 | USD -16,542 | The ETF sold 964 shares of DNLI on 2025-11-20. The shares were previously bought for an average price of USD 15.2367. The Denali Therapeutics Inc shares were sold for 12.6% higher than average price of previous purchases. This sale made a profit of USD 1,854 The average price that the ETF previously sold DNLI share for is USD 17.2877 which is higher than the selling price of USD 17.16 on 2025-11-20. |
| APLS - Apellis Pharmaceuticals Inc | SELL | -848 @ USD 19.54 | USD -16,570 | The ETF sold 848 shares of APLS on 2025-11-20. The shares were previously bought for an average price of USD 20.9322. The Apellis Pharmaceuticals Inc shares were sold for -6.7% lower than average price of previous purchases. This resulted in an overall loss of USD 1,181 The average price that the ETF previously sold APLS share for is USD 25.1343 which is higher than the selling price of USD 19.54 on 2025-11-20. |
| SUPN - Supernus Pharmaceuticals Inc | SELL | -376 @ USD 44.79 | USD -16,841 | The ETF sold 376 shares of SUPN on 2025-11-20. The shares were previously bought for an average price of USD 37.7664. The Supernus Pharmaceuticals Inc shares were sold for 18.6% higher than average price of previous purchases. This sale made a profit of USD 2,641 The average price that the ETF previously sold SUPN share for is USD 36.8537 so the ETF has sold 376 shares on 2025-11-20 at a higher price than the previous selling average. |
| CNTA - Centessa Pharmaceuticals PLC ADR | SELL | -632 @ USD 27.54 | USD -17,405 | The ETF sold 632 shares of CNTA on 2025-11-20. The shares were previously bought for an average price of USD 16.965. The Centessa Pharmaceuticals PLC ADR shares were sold for 62.3% higher than average price of previous purchases. This sale made a profit of USD 6,683 The average price that the ETF previously sold CNTA share for is USD 16.7823 so the ETF has sold 632 shares on 2025-11-20 at a higher price than the previous selling average. |
| MLYS - Mineralys Therapeutics, Inc. Common Stock | SELL | -436 @ USD 41.87 | USD -18,255 | The ETF sold 436 shares of MLYS on 2025-11-20. The shares were previously bought for an average price of USD 20.6009. The Mineralys Therapeutics, Inc. Common Stock shares were sold for 103.2% higher than average price of previous purchases. This sale made a profit of USD 9,273 The average price that the ETF previously sold MLYS share for is USD 16.5248 so the ETF has sold 436 shares on 2025-11-20 at a higher price than the previous selling average. |
| DYN - Dyne Therapeutics Inc | SELL | -956 @ USD 20.12 | USD -19,235 | The ETF sold 956 shares of DYN on 2025-11-20. The shares were previously bought for an average price of USD 13.14. The Dyne Therapeutics Inc shares were sold for 53.1% higher than average price of previous purchases. This sale made a profit of USD 6,673 The average price that the ETF previously sold DYN share for is USD 17.1008 so the ETF has sold 956 shares on 2025-11-20 at a higher price than the previous selling average. |
| DYN - DYNAGREEN EN.PR.GR.H YC 1 | SELL | -956 @ USD 20.12 | USD -19,235 | The ETF sold 956 shares of DYN on 2025-11-20. The shares were previously bought for an average price of USD 13.14. The DYNAGREEN EN.PR.GR.H YC 1 shares were sold for 53.1% higher than average price of previous purchases. This sale made a profit of USD 6,673 The average price that the ETF previously sold DYN share for is USD 17.1008 so the ETF has sold 956 shares on 2025-11-20 at a higher price than the previous selling average. |
| FOLD - Amicus Therapeutics Inc | SELL | -2,036 @ USD 9.45 | USD -19,240 | The ETF sold 2036 shares of FOLD on 2025-11-20. The shares were previously bought for an average price of USD 7.45604. The Amicus Therapeutics Inc shares were sold for 26.7% higher than average price of previous purchases. This sale made a profit of USD 4,060 The average price that the ETF previously sold FOLD share for is USD 8.49753 so the ETF has sold 2036 shares on 2025-11-20 at a higher price than the previous selling average. |
| APGE - Apogee Therapeutics, Inc. Common Stock | SELL | -304 @ USD 63.37 | USD -19,264 | The ETF sold 304 shares of APGE on 2025-11-20. The shares were previously bought for an average price of USD 44.7152. The Apogee Therapeutics, Inc. Common Stock shares were sold for 41.7% higher than average price of previous purchases. This sale made a profit of USD 5,671 The average price that the ETF previously sold APGE share for is USD 40.783 so the ETF has sold 304 shares on 2025-11-20 at a higher price than the previous selling average. |
| IDYA - Ideaya Biosciences Inc | SELL | -588 @ USD 33.16 | USD -19,498 | The ETF sold 588 shares of IDYA on 2025-11-20. The shares were previously bought for an average price of USD 23.8224. The Ideaya Biosciences Inc shares were sold for 39.2% higher than average price of previous purchases. This sale made a profit of USD 5,491 The average price that the ETF previously sold IDYA share for is USD 22.6439 so the ETF has sold 588 shares on 2025-11-20 at a higher price than the previous selling average. |
| RARE - Ultragenyx | SELL | -648 @ USD 31.18 | USD -20,205 | The ETF sold 648 shares of RARE on 2025-11-20. The shares were previously bought for an average price of USD 36.1092. The Ultragenyx shares were sold for -13.7% lower than average price of previous purchases. This resulted in an overall loss of USD 3,194 The average price that the ETF previously sold RARE share for is USD 37.3972 which is higher than the selling price of USD 31.18 on 2025-11-20. |
| RARE - WISETFWTMRARETFP | SELL | -648 @ USD 31.18 | USD -20,205 | The ETF sold 648 shares of RARE on 2025-11-20. The shares were previously bought for an average price of USD 36.1092. The WISETFWTMRARETFP shares were sold for -13.7% lower than average price of previous purchases. This resulted in an overall loss of USD 3,194 The average price that the ETF previously sold RARE share for is USD 37.3972 which is higher than the selling price of USD 31.18 on 2025-11-20. |
| TVTX - Travere Therapeutics Inc | SELL | -588 @ USD 34.73 | USD -20,421 | The ETF sold 588 shares of TVTX on 2025-11-20. The shares were previously bought for an average price of USD 20.5085. The Travere Therapeutics Inc shares were sold for 69.3% higher than average price of previous purchases. This sale made a profit of USD 8,362 The average price that the ETF previously sold TVTX share for is USD 19.012 so the ETF has sold 588 shares on 2025-11-20 at a higher price than the previous selling average. |
| GRAL - GRAIL, LLC | SELL | -240 @ USD 85.65 | USD -20,556 | The ETF sold 240 shares of GRAL on 2025-11-20. The shares were previously bought for an average price of USD 53.7077. The GRAIL, LLC shares were sold for 59.5% higher than average price of previous purchases. This sale made a profit of USD 7,666 The average price that the ETF previously sold GRAL share for is USD 31.7408 so the ETF has sold 240 shares on 2025-11-20 at a higher price than the previous selling average. |
| XENE - Xenon Pharmaceuticals Inc | SELL | -516 @ USD 40.27 | USD -20,779 | The ETF sold 516 shares of XENE on 2025-11-20. The shares were previously bought for an average price of USD 35.7591. The Xenon Pharmaceuticals Inc shares were sold for 12.6% higher than average price of previous purchases. This sale made a profit of USD 2,328 The average price that the ETF previously sold XENE share for is USD 36.2075 so the ETF has sold 516 shares on 2025-11-20 at a higher price than the previous selling average. |
| CGON - CG Oncology, Inc. Common stock | SELL | -512 @ USD 40.71 | USD -20,844 | The ETF sold 512 shares of CGON on 2025-11-20. The shares were previously bought for an average price of USD 30.4302. The CG Oncology, Inc. Common stock shares were sold for 33.8% higher than average price of previous purchases. This sale made a profit of USD 5,263 The average price that the ETF previously sold CGON share for is USD 27.7941 so the ETF has sold 512 shares on 2025-11-20 at a higher price than the previous selling average. |
| IRON - Ironveld Plc | SELL | -232 @ USD 90.35 | USD -20,961 | The ETF sold 232 shares of IRON on 2025-11-20. The shares were previously bought for an average price of USD 60.1404. The Ironveld Plc shares were sold for 50.2% higher than average price of previous purchases. This sale made a profit of USD 7,009 The average price that the ETF previously sold IRON share for is USD 56.467 so the ETF has sold 232 shares on 2025-11-20 at a higher price than the previous selling average. |
| VCYT - Veracyte Inc | SELL | -528 @ USD 40.85 | USD -21,569 | The ETF sold 528 shares of VCYT on 2025-11-20. The shares were previously bought for an average price of USD 31.5345. The Veracyte Inc shares were sold for 29.5% higher than average price of previous purchases. This sale made a profit of USD 4,919 The average price that the ETF previously sold VCYT share for is USD 33.8975 so the ETF has sold 528 shares on 2025-11-20 at a higher price than the previous selling average. |
| ARQT - Arcutis Biotherapeutics Inc | SELL | -792 @ USD 27.33 | USD -21,645 | The ETF sold 792 shares of ARQT on 2025-11-20. The shares were previously bought for an average price of USD 16.7236. The Arcutis Biotherapeutics Inc shares were sold for 63.4% higher than average price of previous purchases. This sale made a profit of USD 8,400 The average price that the ETF previously sold ARQT share for is USD 14.2637 so the ETF has sold 792 shares on 2025-11-20 at a higher price than the previous selling average. |
| TARS - Tarsus Pharmaceuticals Inc | SELL | -284 @ USD 76.98 | USD -21,862 | The ETF sold 284 shares of TARS on 2025-11-20. The shares were previously bought for an average price of USD 50.2789. The Tarsus Pharmaceuticals Inc shares were sold for 53.1% higher than average price of previous purchases. This sale made a profit of USD 7,583 The average price that the ETF previously sold TARS share for is USD 49.8851 so the ETF has sold 284 shares on 2025-11-20 at a higher price than the previous selling average. |
| PRAX - Praxis Precision Medicines Inc | SELL | -140 @ USD 164.09 | USD -22,973 | The ETF sold 140 shares of PRAX on 2025-11-20. The shares were previously bought for an average price of USD 68.4091. The Praxis Precision Medicines Inc shares were sold for 139.9% higher than average price of previous purchases. This sale made a profit of USD 13,395 The average price that the ETF previously sold PRAX share for is USD 50.7954 so the ETF has sold 140 shares on 2025-11-20 at a higher price than the previous selling average. |
| MIRM - Mirum Pharmaceuticals Inc | SELL | -336 @ USD 69.16 | USD -23,238 | The ETF sold 336 shares of MIRM on 2025-11-20. The shares were previously bought for an average price of USD 56.217. The Mirum Pharmaceuticals Inc shares were sold for 23.0% higher than average price of previous purchases. This sale made a profit of USD 4,349 The average price that the ETF previously sold MIRM share for is USD 48.9635 so the ETF has sold 336 shares on 2025-11-20 at a higher price than the previous selling average. |
| AMRX - Amneal Pharmaceuticals, Inc. Class A Common Stock | SELL | -2,108 @ USD 11.515 | USD -24,274 | The ETF sold 2108 shares of AMRX on 2025-11-20. The shares were previously bought for an average price of USD 8.94144. The Amneal Pharmaceuticals, Inc. Class A Common Stock shares were sold for 28.8% higher than average price of previous purchases. This sale made a profit of USD 5,425 The average price that the ETF previously sold AMRX share for is USD 8.69878 so the ETF has sold 2108 shares on 2025-11-20 at a higher price than the previous selling average. |
| SRRK - Scholar Rock Holding Corp | SELL | -640 @ USD 38.02 | USD -24,333 | The ETF sold 640 shares of SRRK on 2025-11-20. The shares were previously bought for an average price of USD 35.1784. The Scholar Rock Holding Corp shares were sold for 8.1% higher than average price of previous purchases. This sale made a profit of USD 1,819 The average price that the ETF previously sold SRRK share for is USD 31.7822 so the ETF has sold 640 shares on 2025-11-20 at a higher price than the previous selling average. |
| ACAD - ACADIA Pharmaceuticals Inc | SELL | -1,128 @ USD 22.9 | USD -25,831 | The ETF sold 1128 shares of ACAD on 2025-11-20. The shares were previously bought for an average price of USD 21.0021. The ACADIA Pharmaceuticals Inc shares were sold for 9.0% higher than average price of previous purchases. This sale made a profit of USD 2,141 The average price that the ETF previously sold ACAD share for is USD 18.0816 so the ETF has sold 1128 shares on 2025-11-20 at a higher price than the previous selling average. |
| ADMA - ADMA Biologics Inc | SELL | -1,600 @ USD 16.36 | USD -26,176 | The ETF sold 1600 shares of ADMA on 2025-11-20. The shares were previously bought for an average price of USD 17.3039. The ADMA Biologics Inc shares were sold for -5.5% lower than average price of previous purchases. This resulted in an overall loss of USD 1,510 The average price that the ETF previously sold ADMA share for is USD 17.7823 which is higher than the selling price of USD 16.36 on 2025-11-20. |
| LGND - Ligand Pharmaceuticals Incorporated | SELL | -132 @ USD 199.03 | USD -26,272 | The ETF sold 132 shares of LGND on 2025-11-20. The shares were previously bought for an average price of USD 136.416. The Ligand Pharmaceuticals Incorporated shares were sold for 45.9% higher than average price of previous purchases. This sale made a profit of USD 8,265 The average price that the ETF previously sold LGND share for is USD 121.267 so the ETF has sold 132 shares on 2025-11-20 at a higher price than the previous selling average. |
| CRNX - Crinetics Pharmaceuticals Inc | SELL | -628 @ USD 41.97 | USD -26,357 | The ETF sold 628 shares of CRNX on 2025-11-20. The shares were previously bought for an average price of USD 35.2671. The Crinetics Pharmaceuticals Inc shares were sold for 19.0% higher than average price of previous purchases. This sale made a profit of USD 4,209 The average price that the ETF previously sold CRNX share for is USD 36.3634 so the ETF has sold 628 shares on 2025-11-20 at a higher price than the previous selling average. |
| IMVT - Immunovant Inc | SELL | -1,172 @ USD 22.79 | USD -26,710 | The ETF sold 1172 shares of IMVT on 2025-11-20. The shares were previously bought for an average price of USD 18.2478. The Immunovant Inc shares were sold for 24.9% higher than average price of previous purchases. This sale made a profit of USD 5,323 The average price that the ETF previously sold IMVT share for is USD 19.9563 so the ETF has sold 1172 shares on 2025-11-20 at a higher price than the previous selling average. |
| AKRO - Akero Therapeutics Inc | SELL | -532 @ USD 54.23 | USD -28,850 | The ETF sold 532 shares of AKRO on 2025-11-20. The shares were previously bought for an average price of USD 49.4687. The Akero Therapeutics Inc shares were sold for 9.6% higher than average price of previous purchases. This sale made a profit of USD 2,533 The average price that the ETF previously sold AKRO share for is USD 38.91 so the ETF has sold 532 shares on 2025-11-20 at a higher price than the previous selling average. |
| CRSP - Crispr Therapeutics AG | SELL | -604 @ USD 49.29 | USD -29,771 | The ETF sold 604 shares of CRSP on 2025-11-20. The shares were previously bought for an average price of USD 52.5889. The Crispr Therapeutics AG shares were sold for -6.3% lower than average price of previous purchases. This resulted in an overall loss of USD 1,993 The average price that the ETF previously sold CRSP share for is USD 43.3077 so the ETF has sold 604 shares on 2025-11-20 at a higher price than the previous selling average. |
| KYMR - Kymera Therapeutics Inc | SELL | -476 @ USD 64.63 | USD -30,764 | The ETF sold 476 shares of KYMR on 2025-11-20. The shares were previously bought for an average price of USD 47.4373. The Kymera Therapeutics Inc shares were sold for 36.2% higher than average price of previous purchases. This sale made a profit of USD 8,184 The average price that the ETF previously sold KYMR share for is USD 37.6518 so the ETF has sold 476 shares on 2025-11-20 at a higher price than the previous selling average. |
| ALKS - Alkermes Plc | SELL | -1,100 @ USD 28.19 | USD -31,009 | The ETF sold 1100 shares of ALKS on 2025-11-20. The shares were previously bought for an average price of USD 30.3462. The Alkermes Plc shares were sold for -7.1% lower than average price of previous purchases. This resulted in an overall loss of USD 2,372 The average price that the ETF previously sold ALKS share for is USD 29.5009 which is higher than the selling price of USD 28.19 on 2025-11-20. |
| COGT - Cogent Biosciences Inc | SELL | -920 @ USD 34.7 | USD -31,924 | The ETF sold 920 shares of COGT on 2025-11-20. The shares were previously bought for an average price of USD 12.0155. The Cogent Biosciences Inc shares were sold for 188.8% higher than average price of previous purchases. This sale made a profit of USD 20,870 The average price that the ETF previously sold COGT share for is USD 8.15644 so the ETF has sold 920 shares on 2025-11-20 at a higher price than the previous selling average. |
| ACLX - Arcellx Inc | SELL | -368 @ USD 89.57 | USD -32,962 | The ETF sold 368 shares of ACLX on 2025-11-20. The shares were previously bought for an average price of USD 72.8831. The Arcellx Inc shares were sold for 22.9% higher than average price of previous purchases. This sale made a profit of USD 6,141 The average price that the ETF previously sold ACLX share for is USD 74.9465 so the ETF has sold 368 shares on 2025-11-20 at a higher price than the previous selling average. |
| PTGX - Protagonist Therapeutics Inc | SELL | -416 @ USD 84.2 | USD -35,027 | The ETF sold 416 shares of PTGX on 2025-11-20. The shares were previously bought for an average price of USD 57.8519. The Protagonist Therapeutics Inc shares were sold for 45.5% higher than average price of previous purchases. This sale made a profit of USD 10,961 The average price that the ETF previously sold PTGX share for is USD 48.9755 so the ETF has sold 416 shares on 2025-11-20 at a higher price than the previous selling average. |
| ARWR - Arrowhead Pharmaceuticals Inc | SELL | -920 @ USD 38.09 | USD -35,043 | The ETF sold 920 shares of ARWR on 2025-11-20. The shares were previously bought for an average price of USD 22.0114. The Arrowhead Pharmaceuticals Inc shares were sold for 73.0% higher than average price of previous purchases. This sale made a profit of USD 14,792 The average price that the ETF previously sold ARWR share for is USD 20.2925 so the ETF has sold 920 shares on 2025-11-20 at a higher price than the previous selling average. |
| KRYS - Krystal Biotech Inc | SELL | -192 @ USD 204.225 | USD -39,211 | The ETF sold 192 shares of KRYS on 2025-11-20. The shares were previously bought for an average price of USD 162.798. The Krystal Biotech Inc shares were sold for 25.4% higher than average price of previous purchases. This sale made a profit of USD 7,954 The average price that the ETF previously sold KRYS share for is USD 165.736 so the ETF has sold 192 shares on 2025-11-20 at a higher price than the previous selling average. |
| PTCT - PTC Therapeutics Inc | SELL | -528 @ USD 76.46 | USD -40,371 | The ETF sold 528 shares of PTCT on 2025-11-20. The shares were previously bought for an average price of USD 55.8034. The PTC Therapeutics Inc shares were sold for 37.0% higher than average price of previous purchases. This sale made a profit of USD 10,907 The average price that the ETF previously sold PTCT share for is USD 48.7449 so the ETF has sold 528 shares on 2025-11-20 at a higher price than the previous selling average. |
| PCVX - Vaxcyte Inc | SELL | -864 @ USD 47.67 | USD -41,187 | The ETF sold 864 shares of PCVX on 2025-11-20. The shares were previously bought for an average price of USD 44.6531. The Vaxcyte Inc shares were sold for 6.8% higher than average price of previous purchases. This sale made a profit of USD 2,607 The average price that the ETF previously sold PCVX share for is USD 52.6433 which is higher than the selling price of USD 47.67 on 2025-11-20. |
| RYTM - Rhythm Pharmaceuticals Inc | SELL | -444 @ USD 100.66 | USD -44,693 | The ETF sold 444 shares of RYTM on 2025-11-20. The shares were previously bought for an average price of USD 76.7753. The Rhythm Pharmaceuticals Inc shares were sold for 31.1% higher than average price of previous purchases. This sale made a profit of USD 10,605 The average price that the ETF previously sold RYTM share for is USD 62.4941 so the ETF has sold 444 shares on 2025-11-20 at a higher price than the previous selling average. |
| AXSM - Axsome Therapeutics Inc | SELL | -332 @ USD 143.31 | USD -47,579 | The ETF sold 332 shares of AXSM on 2025-11-20. The shares were previously bought for an average price of USD 116.151. The Axsome Therapeutics Inc shares were sold for 23.4% higher than average price of previous purchases. This sale made a profit of USD 9,017 The average price that the ETF previously sold AXSM share for is USD 103.103 so the ETF has sold 332 shares on 2025-11-20 at a higher price than the previous selling average. |
| NUVL - Nuvalent Inc | SELL | -444 @ USD 108.01 | USD -47,956 | The ETF sold 444 shares of NUVL on 2025-11-20. The shares were previously bought for an average price of USD 83.1304. The Nuvalent Inc shares were sold for 29.9% higher than average price of previous purchases. This sale made a profit of USD 11,047 The average price that the ETF previously sold NUVL share for is USD 77.9202 so the ETF has sold 444 shares on 2025-11-20 at a higher price than the previous selling average. |
| MRUS - Merus BV | SELL | -504 @ USD 95.98 | USD -48,374 | The ETF sold 504 shares of MRUS on 2025-11-20. The shares were previously bought for an average price of USD 65.4904. The Merus BV shares were sold for 46.6% higher than average price of previous purchases. This sale made a profit of USD 15,367 The average price that the ETF previously sold MRUS share for is USD 47.3328 so the ETF has sold 504 shares on 2025-11-20 at a higher price than the previous selling average. |
| CYTK - Cytokinetics Inc | SELL | -792 @ USD 63.5 | USD -50,292 | The ETF sold 792 shares of CYTK on 2025-11-20. The shares were previously bought for an average price of USD 43.8796. The Cytokinetics Inc shares were sold for 44.7% higher than average price of previous purchases. This sale made a profit of USD 15,539 The average price that the ETF previously sold CYTK share for is USD 45.2174 so the ETF has sold 792 shares on 2025-11-20 at a higher price than the previous selling average. |
| HALO - Halozyme Therapeutics Inc | SELL | -776 @ USD 68.97 | USD -53,521 | The ETF sold 776 shares of HALO on 2025-11-20. The shares were previously bought for an average price of USD 60.1236. The Halozyme Therapeutics Inc shares were sold for 14.7% higher than average price of previous purchases. This sale made a profit of USD 6,865 The average price that the ETF previously sold HALO share for is USD 59.343 so the ETF has sold 776 shares on 2025-11-20 at a higher price than the previous selling average. |
| MRNA - Moderna Inc | SELL | -2,584 @ USD 22.36 | USD -57,778 | The ETF sold 2584 shares of MRNA on 2025-11-20. The shares were previously bought for an average price of USD 29.0315. The Moderna Inc shares were sold for -23.0% lower than average price of previous purchases. This resulted in an overall loss of USD 17,239 The average price that the ETF previously sold MRNA share for is USD 33.6201 which is higher than the selling price of USD 22.36 on 2025-11-20. |
| RNA - Avidity Biosciences Inc | SELL | -852 @ USD 70.65 | USD -60,194 | The ETF sold 852 shares of RNA on 2025-11-20. The shares were previously bought for an average price of USD 38.752. The Avidity Biosciences Inc shares were sold for 82.3% higher than average price of previous purchases. This sale made a profit of USD 27,177 The average price that the ETF previously sold RNA share for is USD 32.7799 so the ETF has sold 852 shares on 2025-11-20 at a higher price than the previous selling average. |
| BNTX - BioNTech SE | SELL | -668 @ USD 96.97 | USD -64,776 | The ETF sold 668 shares of BNTX on 2025-11-20. The shares were previously bought for an average price of USD 105.165. The BioNTech SE shares were sold for -7.8% lower than average price of previous purchases. This resulted in an overall loss of USD 5,474 The average price that the ETF previously sold BNTX share for is USD 104.463 which is higher than the selling price of USD 96.97 on 2025-11-20. |
| BMRN - Biomarin Pharmaceutical Inc | SELL | -1,272 @ USD 52.48 | USD -66,755 | The ETF sold 1272 shares of BMRN on 2025-11-20. The shares were previously bought for an average price of USD 58.0445. The Biomarin Pharmaceutical Inc shares were sold for -9.6% lower than average price of previous purchases. This resulted in an overall loss of USD 7,078 The average price that the ETF previously sold BMRN share for is USD 61.9504 which is higher than the selling price of USD 52.48 on 2025-11-20. |
| JAZZ - Jazz Pharmaceuticals PLC | SELL | -404 @ USD 175.74 | USD -70,999 | The ETF sold 404 shares of JAZZ on 2025-11-20. The shares were previously bought for an average price of USD 124.63. The Jazz Pharmaceuticals PLC shares were sold for 41.0% higher than average price of previous purchases. This sale made a profit of USD 20,648 The average price that the ETF previously sold JAZZ share for is USD 122.822 so the ETF has sold 404 shares on 2025-11-20 at a higher price than the previous selling average. |
| EXEL - Exelixis Inc | SELL | -1,788 @ USD 41.78 | USD -74,703 | The ETF sold 1788 shares of EXEL on 2025-11-20. The shares were previously bought for an average price of USD 41.0199. The Exelixis Inc shares were sold for 1.9% higher than average price of previous purchases. This sale made a profit of USD 1,359 The average price that the ETF previously sold EXEL share for is USD 36.4039 so the ETF has sold 1788 shares on 2025-11-20 at a higher price than the previous selling average. |
| IONS - Ionis Pharmaceuticals Inc | SELL | -1,064 @ USD 73.12 | USD -77,800 | The ETF sold 1064 shares of IONS on 2025-11-20. The shares were previously bought for an average price of USD 49.4247. The Ionis Pharmaceuticals Inc shares were sold for 47.9% higher than average price of previous purchases. This sale made a profit of USD 25,212 The average price that the ETF previously sold IONS share for is USD 40.4065 so the ETF has sold 1064 shares on 2025-11-20 at a higher price than the previous selling average. |
| VTRS - Viatris Inc | SELL | -7,772 @ USD 10.19 | USD -79,197 | The ETF sold 7772 shares of VTRS on 2025-11-20. The shares were previously bought for an average price of USD 9.63596. The Viatris Inc shares were sold for 5.7% higher than average price of previous purchases. This sale made a profit of USD 4,306 The average price that the ETF previously sold VTRS share for is USD 10.5041 which is higher than the selling price of USD 10.19 on 2025-11-20. |
| MDGL - Madrigal Pharmaceuticals Inc | SELL | -148 @ USD 542.12 | USD -80,234 | The ETF sold 148 shares of MDGL on 2025-11-20. The shares were previously bought for an average price of USD 357.38. The Madrigal Pharmaceuticals Inc shares were sold for 51.7% higher than average price of previous purchases. This sale made a profit of USD 27,342 The average price that the ETF previously sold MDGL share for is USD 337.342 so the ETF has sold 148 shares on 2025-11-20 at a higher price than the previous selling average. |
| SMMT - Summit Therapeutics PLC | SELL | -4,948 @ USD 16.45 | USD -81,395 | The ETF sold 4948 shares of SMMT on 2025-11-20. The shares were previously bought for an average price of USD 21.2498. The Summit Therapeutics PLC shares were sold for -22.6% lower than average price of previous purchases. This resulted in an overall loss of USD 23,749 The average price that the ETF previously sold SMMT share for is USD 20.0293 which is higher than the selling price of USD 16.45 on 2025-11-20. |
| BBIO - BridgeBio Pharma Inc | SELL | -1,276 @ USD 64.62 | USD -82,455 | The ETF sold 1276 shares of BBIO on 2025-11-20. The shares were previously bought for an average price of USD 45.6873. The BridgeBio Pharma Inc shares were sold for 41.4% higher than average price of previous purchases. This sale made a profit of USD 24,158 The average price that the ETF previously sold BBIO share for is USD 34.3845 so the ETF has sold 1276 shares on 2025-11-20 at a higher price than the previous selling average. |
| GH - Guardant Health Inc | SELL | -832 @ USD 100.3 | USD -83,450 | The ETF sold 832 shares of GH on 2025-11-20. The shares were previously bought for an average price of USD 57.0788. The Guardant Health Inc shares were sold for 75.7% higher than average price of previous purchases. This sale made a profit of USD 35,960 The average price that the ETF previously sold GH share for is USD 41.2262 so the ETF has sold 832 shares on 2025-11-20 at a higher price than the previous selling average. |
| ASND - Ascendis Pharma AS | SELL | -404 @ USD 209.55 | USD -84,658 | The ETF sold 404 shares of ASND on 2025-11-20. The shares were previously bought for an average price of USD 179.659. The Ascendis Pharma AS shares were sold for 16.6% higher than average price of previous purchases. This sale made a profit of USD 12,076 The average price that the ETF previously sold ASND share for is USD 155.306 so the ETF has sold 404 shares on 2025-11-20 at a higher price than the previous selling average. |
| RVMD - Revolution Medicines Inc | SELL | -1,248 @ USD 69.88 | USD -87,210 | The ETF sold 1248 shares of RVMD on 2025-11-20. The shares were previously bought for an average price of USD 42.6919. The Revolution Medicines Inc shares were sold for 63.7% higher than average price of previous purchases. This sale made a profit of USD 33,931 The average price that the ETF previously sold RVMD share for is USD 42.1895 so the ETF has sold 1248 shares on 2025-11-20 at a higher price than the previous selling average. |
| SNY - Sanofi ADR | SELL | -1,788 @ USD 48.89 | USD -87,415 | The ETF sold 1788 shares of SNY on 2025-11-20. The shares were previously bought for an average price of USD 50.0547. The Sanofi ADR shares were sold for -2.3% lower than average price of previous purchases. This resulted in an overall loss of USD 2,082 The average price that the ETF previously sold SNY share for is USD 49.8778 which is higher than the selling price of USD 48.89 on 2025-11-20. |
| NBIX - Neurocrine Biosciences Inc | SELL | -660 @ USD 138.98 | USD -91,727 | The ETF sold 660 shares of NBIX on 2025-11-20. The shares were previously bought for an average price of USD 130.358. The Neurocrine Biosciences Inc shares were sold for 6.6% higher than average price of previous purchases. This sale made a profit of USD 5,691 The average price that the ETF previously sold NBIX share for is USD 125.45 so the ETF has sold 660 shares on 2025-11-20 at a higher price than the previous selling average. |
| ROIV - Roivant Sciences Ltd | SELL | -4,532 @ USD 20.27 | USD -91,864 | The ETF sold 4532 shares of ROIV on 2025-11-20. The shares were previously bought for an average price of USD 13.2785. The Roivant Sciences Ltd shares were sold for 52.7% higher than average price of previous purchases. This sale made a profit of USD 31,685 The average price that the ETF previously sold ROIV share for is USD 11.6073 so the ETF has sold 4532 shares on 2025-11-20 at a higher price than the previous selling average. |
| RPRX - Royalty Pharma Plc | SELL | -2,868 @ USD 38.39 | USD -110,103 | The ETF sold 2868 shares of RPRX on 2025-11-20. The shares were previously bought for an average price of USD 35.7649. The Royalty Pharma Plc shares were sold for 7.3% higher than average price of previous purchases. This sale made a profit of USD 7,529 The average price that the ETF previously sold RPRX share for is USD 29.918 so the ETF has sold 2868 shares on 2025-11-20 at a higher price than the previous selling average. |
| MEDP - Medpace Holdings Inc | SELL | -188 @ USD 586.16 | USD -110,198 | The ETF sold 188 shares of MEDP on 2025-11-20. The shares were previously bought for an average price of USD 402.933. The Medpace Holdings Inc shares were sold for 45.5% higher than average price of previous purchases. This sale made a profit of USD 34,447 The average price that the ETF previously sold MEDP share for is USD 358.83 so the ETF has sold 188 shares on 2025-11-20 at a higher price than the previous selling average. |
| ILMN - Illumina Inc | SELL | -1,020 @ USD 119.26 | USD -121,645 | The ETF sold 1020 shares of ILMN on 2025-11-20. The shares were previously bought for an average price of USD 98.4585. The Illumina Inc shares were sold for 21.1% higher than average price of previous purchases. This sale made a profit of USD 21,218 The average price that the ETF previously sold ILMN share for is USD 106.102 so the ETF has sold 1020 shares on 2025-11-20 at a higher price than the previous selling average. |
| INCY - Incyte Corporation | SELL | -1,300 @ USD 101.76 | USD -132,288 | The ETF sold 1300 shares of INCY on 2025-11-20. The shares were previously bought for an average price of USD 75.5735. The Incyte Corporation shares were sold for 34.7% higher than average price of previous purchases. This sale made a profit of USD 34,042 The average price that the ETF previously sold INCY share for is USD 71.261 so the ETF has sold 1300 shares on 2025-11-20 at a higher price than the previous selling average. |
| UTHR - United Therapeutics Corporation | SELL | -300 @ USD 474.72 | USD -142,416 | The ETF sold 300 shares of UTHR on 2025-11-20. The shares were previously bought for an average price of USD 348.799. The United Therapeutics Corporation shares were sold for 36.1% higher than average price of previous purchases. This sale made a profit of USD 37,776 The average price that the ETF previously sold UTHR share for is USD 347.636 so the ETF has sold 300 shares on 2025-11-20 at a higher price than the previous selling average. |
| BIIB - Biogen Inc | SELL | -976 @ USD 168.18 | USD -164,144 | The ETF sold 976 shares of BIIB on 2025-11-20. The shares were previously bought for an average price of USD 139.485. The Biogen Inc shares were sold for 20.6% higher than average price of previous purchases. This sale made a profit of USD 28,006 The average price that the ETF previously sold BIIB share for is USD 142.136 so the ETF has sold 976 shares on 2025-11-20 at a higher price than the previous selling average. |
| ARGX - argenx NV ADR | SELL | -204 @ USD 918.5 | USD -187,374 | The ETF sold 204 shares of ARGX on 2025-11-20. The shares were previously bought for an average price of USD 652.847. The argenx NV ADR shares were sold for 40.7% higher than average price of previous purchases. This sale made a profit of USD 54,193 The average price that the ETF previously sold ARGX share for is USD 627.704 so the ETF has sold 204 shares on 2025-11-20 at a higher price than the previous selling average. |
| INSM - Insmed Inc | SELL | -1,404 @ USD 199.64 | USD -280,295 | The ETF sold 1404 shares of INSM on 2025-11-20. The shares were previously bought for an average price of USD 123.443. The Insmed Inc shares were sold for 61.7% higher than average price of previous purchases. This sale made a profit of USD 106,981 The average price that the ETF previously sold INSM share for is USD 81.4297 so the ETF has sold 1404 shares on 2025-11-20 at a higher price than the previous selling average. |
| AZN - AstraZeneca PLC | SELL | -3,444 @ USD 88.68 | USD -305,414 | The ETF sold 3444 shares of AZN on 2025-11-20. The shares were previously bought for an average price of USD 75.3788. The AstraZeneca PLC shares were sold for 17.6% higher than average price of previous purchases. This sale made a profit of USD 45,809 The average price that the ETF previously sold AZN share for is USD 71.5824 so the ETF has sold 3444 shares on 2025-11-20 at a higher price than the previous selling average. |
| ALNY - Alnylam Pharmaceuticals Inc | SELL | -864 @ USD 445.79 | USD -385,163 | The ETF sold 864 shares of ALNY on 2025-11-20. The shares were previously bought for an average price of USD 378.897. The Alnylam Pharmaceuticals Inc shares were sold for 17.7% higher than average price of previous purchases. This sale made a profit of USD 57,796 The average price that the ETF previously sold ALNY share for is USD 274.717 so the ETF has sold 864 shares on 2025-11-20 at a higher price than the previous selling average. |
| REGN - Regeneron Pharmaceuticals Inc | SELL | -688 @ USD 737 | USD -507,056 | The ETF sold 688 shares of REGN on 2025-11-20. The shares were previously bought for an average price of USD 629.096. The Regeneron Pharmaceuticals Inc shares were sold for 17.2% higher than average price of previous purchases. This sale made a profit of USD 74,238 The average price that the ETF previously sold REGN share for is USD 618.482 so the ETF has sold 688 shares on 2025-11-20 at a higher price than the previous selling average. |
| VRTX - Vertex Pharmaceuticals Inc | SELL | -1,408 @ USD 422.32 | USD -594,627 | The ETF sold 1408 shares of VRTX on 2025-11-20. The shares were previously bought for an average price of USD 416.007. The Vertex Pharmaceuticals Inc shares were sold for 1.5% higher than average price of previous purchases. This sale made a profit of USD 8,889 The average price that the ETF previously sold VRTX share for is USD 471.942 which is higher than the selling price of USD 422.32 on 2025-11-20. |
| GILD - Guild Esports Plc | SELL | -4,872 @ USD 124.99 | USD -608,951 | The ETF sold 4872 shares of GILD on 2025-11-20. The shares were previously bought for an average price of USD 113.425. The Guild Esports Plc shares were sold for 10.2% higher than average price of previous purchases. This sale made a profit of USD 56,345 The average price that the ETF previously sold GILD share for is USD 101.305 so the ETF has sold 4872 shares on 2025-11-20 at a higher price than the previous selling average. |
| AMGN - Amgen Inc | SELL | -1,912 @ USD 336.07 | USD -642,566 | The ETF sold 1912 shares of AMGN on 2025-11-20. The shares were previously bought for an average price of USD 289.832. The Amgen Inc shares were sold for 16.0% higher than average price of previous purchases. This sale made a profit of USD 88,407 The average price that the ETF previously sold AMGN share for is USD 301.396 so the ETF has sold 1912 shares on 2025-11-20 at a higher price than the previous selling average. |